PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy were superior to PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line therapy in patients with advanced non-small cell lung cancer. This evidence concerns the gene CD274 and non-small cell lung carcinoma.